Case series describes COVID-19-associated Mucormycosis in Arkansas patients

A field report presented as a case series described patients in Arkansas diagnosed with COVID-19-associated Mucormycosis. The report did not specify the study phase, sample size, or duration of follow-up. No comparator group was defined, and the intervention was exposure to COVID-19 infection.

The main outcome was a description of the cases. The report stated that cases were described but did not provide absolute numbers, effect sizes, p-values, or confidence intervals. No statistical analysis was performed.

Safety and tolerability data were not reported. The report's key limitations include its descriptive nature, lack of a comparison group, and absence of reported sample size. No funding or conflicts of interest were disclosed. The practice relevance was not reported. This evidence serves only to document the occurrence of these cases in a specific region and cannot inform clinical management or risk assessment.